2001
Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy
Holman R, Paddock C, Curns A, Krebs J, McQuiston J, Childs J. Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy. The Journal Of Infectious Diseases 2001, 184: 1437-1444. PMID: 11709786, DOI: 10.1086/324372.Peer-Reviewed Original ResearchConceptsRisk factorsFatal Rocky Mountain Spotted FeverRocky Mountain Spotted FeverOnset of symptomsCase fatality rateTetracycline-class antibioticsPrimary therapyClinical characteristicsOlder patientsAppropriate therapyRMSF casesNonfatal casesNational surveillanceHigh riskSpotted FeverPatientsEffective antibioticsTherapyDeathFeverAntibioticsTreatmentSymptomsFactorsDisease
1998
Human ehrlichiosis in central Europe.
Lotric-Furlan S, Petrovec M, Avsic-Zupanc T, Nicholson W, Sumner J, Childs J, Strle F. Human ehrlichiosis in central Europe. Wiener Klinische Wochenschrift 1998, 110: 894-7. PMID: 10048172.Peer-Reviewed Original ResearchConceptsFebrile illnessTick biteHGE agentPresence of infectionUniversity Medical CenterBlood smear examinationHuman granulocytic ehrlichiosis (HGE) agentEhrlichiosis casesAcute human diseaseClinical characteristicsAntibiotic therapyDisease coursePhysician awarenessProspective studyLaboratory findingsDifferential diagnosisMedical CenterSmear examinationHuman diseasesHuman ehrlichiosisNumber of casesPatientsHuman infectionsInfectious diseasesDisease